Data in Biotech

In this episode of Data in Biotech, host Ross Katz sits down with Eshani Galermo, Staff Scientist at SCIEX, to explore the next generation of mass spectrometry in pharma and biopharma. Eshani explains how innovations like the ZenoTOF 8600 are redefining sensitivity, selectivity, and workflow efficiency in bioanalytical chemistry. Discover how high-resolution accurate mass (HRAM) systems are unlocking new capabilities in drug discovery, clinical studies, and regulatory science. What you'll learn in this episode: >> Why traditional mass spectrometry falls short in modern bioanalysis >> How the ZenoTOF 8600 enhances sensitivity and reduces sample volume needs >> The role of high-resolution systems in detecting complex drug metabolites >> How automation tools are streamlining workflows for bioanalytical scientists >> The complementary role of AI and ML in mass spec data analysis Meet our guest Eshani Galermo is a Staff Scientist at SCIEX, where she leads global strategic marketing initiatives for pharma and biopharma quant applications. With deep expertise in bioanalytical chemistry and mass spectrometry, she has held multiple scientific roles across SCIEX, Emery Pharma, and Genentech.  About the host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Eshani Galermo on LinkedIn  Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

In this episode of Data in Biotech, Ross Katz chats with Wesley Tatum, Principal Engineer at Serán BioScience, about the intricacies of formulating low-solubility drug products. They explore the science behind amorphous solid dispersions, how data informs formulation choices, and why balancing performance, manufacturability, and stability is critical in modern drug development. What you'll learn in this episode: >> How amorphous solid dispersions improve solubility and stability in drug products >> Why formulation decisions hinge on early data collection and modeling >> The role of data infrastructure in formulation R&D and knowledge transfer >> How Serán BioScience collaborates closely with clients to solve complex drug development challenges >> Where AI and automation are (and aren’t yet) transforming pharmaceutical formulation Meet our guest Wesley Tatum is a Materials Science PhD researcher working at the crossroads of materials innovation, data science, and machine learning. His work focuses on organic materials and polymer dispersions, and he’s especially passionate about how modern computational tools can transform the way we characterize and understand new materials. Wesley is well versed in PyTorch, Scikit-Learn, and a range of open-source scientific computing libraries, and he brings deep experience in chemical analysis, microscopy, and image analysis.  About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Wesley Tatum on LinkedIn  Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

Dr. Anil Kane, Executive Director at Thermo Fisher Scientific, dives into the transformative impact of AI and machine learning in drug development. He explains how predictive modeling is eliminating traditional trial-and-error methods, significantly cutting costs and timelines. Anil shares insights on accelerated stability testing with the ASAP program and the integration of digital tools to enhance manufacturing efficiency. He also discusses the balance between human expertise and AI, and the exciting future of digital transformation in pharmaceuticals.

In this episode of Data in Biotech, host Ross Katz sits down with John Liberty, Senior Bioanalysis Technical Sales Consultant at Thermo Fisher Scientific. They dive deep into how Watson LIMS™ supports regulated bioanalysis workflows, the evolving role of lab automation, and how Connect Enterprise aims to unify biotech digital ecosystems. What you'll learn in this episode: >> Why Watson LIMS is purpose-built for bioanalysis and how it enhances compliance and data traceability. >> The role of lab automation in boosting productivity and reducing manual tasks. >> How Connect Enterprise integrates lab systems across vendors into a seamless workflow.  >> Key considerations for implementing LIMS in startup versus established biotech environments. >> The ROI of digital lab solutions in supporting scalable, compliant biotech operations. Meet Our Guests John Liberty is a GMP-trained scientist with a strong focus on ELISA method development, validation, and transfer. He pairs his hands-on scientific background with experience in project management, CRO coordination, data analysis, and training, making him someone who really understands how work moves from the lab bench to real-world application. John has also spent time on the product and customer side, doing technical sales and demos for Watson LIMS™ software, giving him a rare blend of technical depth and communication skills. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with John Liberty  on LinkedIn  Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

In this discussion, Hugo Shi, CTO of Saturn Cloud and co-founder of Anaconda, and Ilya Burkov, Global Head of Healthcare at Nebius, delve into the critical intersection of AI and biotech. They explore how specialized cloud infrastructure can alleviate challenges like GPU scarcity and compliance for biotech teams. Real-world applications of AI in gene editing and medical imaging highlight their innovative approaches. Notably, they reveal how choosing Nebius can significantly reduce costs—by up to 70%—compared to traditional hyperscalers.

Robin Rohm, CEO and Co-Founder of Apheris, joins Ross Katz to explore how federated learning is unlocking secure, cross-company collaboration in pharma. Discover how Apheris is enabling biopharma leaders to train cutting-edge co-folding models without sharing sensitive data, why AlphaFold 3 wasn’t enough, and what OpenFold 3 means for the future of AI in drug discovery. ​​What You'll Learn in This Episode >> Why federated learning is a game-changer for pharma data sharing and AI-driven research >> How OpenFold 3 builds on AlphaFold’s legacy to solve the protein-ligand interaction challenge >> The role of structural benchmarking in model development and validation >> How Apheris enables privacy-preserving collaboration between major pharma players >>The importance of high-quality, proprietary datasets in advancing co-folding model accuracy Meet Our Guest Robin Rohm is the CEO and Co-Founder of Apheris, a leader in federated data networks for life sciences. With a background in mathematics and computational genomics, Robin is advancing secure AI collaboration in pharma and biotech. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Robin Roehm  on LinkedIn  Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

In a fascinating discussion, Alex Telford and Maged Ahmed, co-founders of Convoke, explore the automation of knowledge work in biopharma. With Alex's background in life sciences consulting and Maged's expertise in AI and data infrastructure, they reveal how Convoke unifies diverse biotech data to enhance drug development. They share intriguing use cases, such as optimizing clinical trial design and improving regulatory writing, while discussing the importance of structured outputs, iterative processes, and trust in AI-driven insights.

Dr. Aliza Apple, VP of Catalyze360 AI/ML at Eli Lilly, joins Ross Katz to unveil TuneLab—a first-of-its-kind federated learning platform accelerating preclinical drug discovery. Learn how Lilly’s billion-dollar models are empowering early-stage biotechs, the science behind federated learning, and what this means for the future of pharmaceutical R&D. ​​What You'll Learn in This Episode: >> How Eli Lilly's TuneLab democratizes access to proprietary AI models trained on decades of pharmaceutical data >> What federated learning means for IP protection and collaborative data sharing in biotech >> Which two key use cases are driving TuneLab’s impact today: small molecule ADME and antibody developability >> How TuneLab’s early adopters like Firefly Bio and Superluminal are shaping the platform’s evolution >> Why generalizability—not just accuracy—is the true power of collaborative AI in drug development Meet Our Guest Dr. Aliza Apple is VP of Catalyze360 AI/ML at Eli Lilly and a biotech trailblazer with deep roots in AI-driven drug discovery. She has led initiatives from founding startups to heading Lilly Gateway Labs and now pioneers innovation at the intersection of data and biotech. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Aliza Apple  on LinkedIn  Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

In this episode of Data in Biotech, host Ross Katz talks with Jesper Ryge, Director of Computational Biology at Merck Germany. Jesper shares his journey from neuroscience labs to leading computational teams, offering deep insights into disease modeling, target discovery, and multi-omics integration. Discover how AI and spatial transcriptomics are shaping the future of pharma R&D. ​​What You'll Learn in This Episode >> How single-cell and spatial transcriptomics enhance disease mechanism discovery >> Why data integration and knowledge graphs are critical for target validation >> How computational biology teams interface with wet lab research >> What makes Merck Germany's data strategy unique in biotech >> How generative AI is changing how pharma interprets complex datasets Meet Our Guest Jesper Ryge is Director of Computational Biology at Merck Germany. A biophysicist by training, he brings deep expertise in neuroscience, single-cell analysis, and bioinformatics to pharmaceutical R&D. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyFind out more about MerckConnect with Jesper Ryge on LinkedIn  Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

To mark our 50th episode, host Ross Katz brings back three visionary leaders—Dave Johnson (Dash Bio), Wolfgang Halter (Merck Life Science), and Jacob Oppenheim (RAVen)—together for a reflection on the evolution of biotech. They unpack the realities behind AI hype, the future of data-driven innovation, and what’s really changing in drug development. ​​What You'll Learn in This Episode: >> Where real innovation is emerging across startups, big tech, and academia >> The biggest misconceptions about data in biotech—and why they persist >> What it takes to build trust in AI-powered biotech tools >> Why progress in biotech depends as much on execution as it does on breakthroughs >> How industry veterans see the future of automation, regulation, and global competition Meet Our Guests Dave Johnson is CEO and Co-Founder of Dash Bio and former Chief Data & AI Officer at Moderna. He’s pioneering automation in clinical bioanalysis to accelerate drug development. Wolfgang Halter leads Data Science at Merck Life Science, developing tools like BayBE to optimize R&D through smarter data modeling and open-source innovation. Jacob Oppenheim is a Venture Partner at RAVen and co-founder of Fresnel. With a PhD in Biological Physics, he champions the transition to digital-native biopharma. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Dave Johnson  on LinkedIn Connect with Wolfgang Halter on LinkedInConnect with Jacob Oppenheim on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.